Non-liver-related deaths higher among HIV/HCV coinfected patients despite DAA treatment
The direct-acting antiviral (DAA) era has balanced the sustained virological response (SVR) and liver-related mortality risk between patients monoinfected with the hepatitis C virus (HCV) and those with HIV coinfections, a recent study has found. However, those with HCV/HIV coinfections continue to experience a higher overall mortality risk, driven mainly by non-liver-related deaths.
